Dose-dependent and disease-modifying effects of striatal infusion of cholesterol in Huntington's disease
Giulia BiroliniiD, Marta ValenzaiD, Eleonora Di PaoloiD, Elena VezzoliiD, Francesca TalpoiD, Claudia ManiezziiD, Claudio CacciaiD, Valerio LeoniiD, Vittoria Dickinson BocchiiD, Paola ConfortiiD, Elisa SogneiD, Lara Petricca, Cristina CariuloiD, Margherita Verani, Andrea CaricasoleiD, Andrea FalquiiD, Gerardo Rosario BiellaiD, Elena F. CattaneoiD
Abstract
A variety of pathophysiological mechanisms are implicated in Huntingtons disease (HD). Among them, reduced cholesterol biosynthesis has been detected in the HD mouse brain from pre-symptomatic stages, leading to diminished cholesterol synthesis, particularly in the striatum. In addition, systemic injection of cholesterol-loaded brain-permeable nanoparticles ameliorates synaptic and cognitive function in a transgenic mouse model of HD. To identify an appropriate treatment regimen and gain mechanistic insights into the beneficial activity of exogenous cholesterol in the HD brain, we employed osmotic mini-pumps to infuse three escalating doses of cholesterol directly into the striatum of HD mice in a continuous and rate-controlled manner. All tested doses prevented cognitive decline, while amelioration of disease-related motor defects was dose-dependent. In parallel, we found morphological and functional recovery of synaptic transmission involving both excitatory and inhibitory synapses of striatal medium spiny neurons. The treatment also enhanced endogenous cholesterol biosynthesis and clearance of mutant Huntingtin aggregates. These results indicate that cholesterol infusion to the striatum can exert a dose-dependent, disease-modifying effect and may be therapeutically relevant in HD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington disease
Giulia Birolini, Marta Valenza, … Elena F. Cattaneo·Pharmacological ResearchPeer-reviewed·Jun 17, 2023
- M2 Cortex-Dorsolateral striatum stimulation reverses motor symptoms and synaptic deficits in Huntington's Disease
Sara Fernández‐García, Sara Conde-Berriozabal, … Mercè Masana·eLifePeer-reviewed·Oct 5, 2020
- Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles forcholesterol delivery in Huntington disease
Giulia Birolini, Marta Valenza, … Elena F. Cattaneo·Journal of Controlled ReleasePeer-reviewed·Jan 7, 2021
- SREBP2 delivery to striatal astrocytes normalizes transcription of cholesterol biosynthesis genes and ameliorates pathological features in Huntington's disease
Giulia Birolini, Gianluca Verlengia, … Marta Valenza·bioRxiv·Nov 23, 2020
- Enhanced Hippocampal Spare Capacity in Q175DN Mice Despite Elevated mHTT Aggregation
Melissa A Solem, Ross J. Pelzel, … Rocío Gómez‐Pastor·bioRxiv·Oct 14, 2024
- Peripheral Htt silencing does not ameliorate central signs of disease in the B6. HttQ111/+ mouse model of Huntington’s Disease
Sydney R. Coffey, Robert M. Bragg, … Jeffrey B. Carroll·PLoS ONEPeer-reviewed·Apr 28, 2017